MicroRNAs AS BIOMARKERS OF MIOCARDITIS AND DILATING CARDIOMIOPATHY

DOI: https://doi.org/10.29296/24999490-2023-04-03

O.M. Ryabinina, E.A. Melnikova, O.V. Makarova
Scientific Research Institute of Human Morphology named after Akad. A.P. Avtsyn FGBNU «Russian Scientific Center
of Surgery named after akad. B.V. Petrovsky», Tsyurupy str., 3, Moscow, 117418, Russian Federation

Introduction. Currently, clinical diagnosis of myocarditis is a difficult task. The diagnosis of the disease is made on the basis of category IV criteria, which include data of electrocardiography, Holter monitoring, echocardiography and MRI, laboratory biomarkers of necrosis, inflammation and heart failure, morphological study of endomyocardial biopsy specimens. Objective. To analyze literature data on the potential of different miRNAs determination for diagnostics of myocarditis. Material and methods. Literature search was carried out in Google Scholar for the last 15 years. Results and discussion. miR-208b in blood mononuclear and cardiac tissues can be considered as a promising marker for myocarditis diagnosis, and circulating miR-27b-3p, miR-126-3p, miR-142- 5p and miR-143-3p for DCM diagnosis. The presence of miR-15b-5p and miR-106a-5p in plasma allows us to distinguish between patients with ischemic and idiopathic DCM. Acute viral myocarditis is characterized by the presence of miR-208b and miR-499-5p in cardiac tissues, while fulminant myocarditis is characterized by increased levels of circulating miR-30a, miR-192, miR-146a, miR-155 and miR-320a. It should be noted that no specific miRNAs for chronic myocarditis have been found.
Keywords: 
myocarditis, dilated cardiomyopathy, diagnosis, miRNAs
Список литературы: 
  1. Арутюнов Г.П., Палеев Ф.Н., Моисеева О.М., Драгунов Д.О., Соколова А.В., Арутюнов А.Г., Жиров И.В., Благова О.В., Привалова Е.В., Габрусенко С.А., Гарганеева А.А., Гендлин Г.Е., Гиляревский С.Р., Дупляков Д.В., Зайратьянц О.В., Каратеев Д.Е., Козиолова Н.А., Космачева Е.Д., Кочетов А.Г., Лопатин Ю.М., Мелехов А.В., Митрофанова Л.Б., Нарусов О.Ю., Насонова С.Н., Недоступ А.В., Никулина С.Ю., Орлова Я.А., Потешкина Н.Г., Ребров А.П., Саидова М.А., Седов В.П., Синицын В.Е., Ситникова М.Ю., Скворцов А.А., Скибицкий В.В., Стукалова О.В., Тарловская Е.И., Терещенко С.Н., Усов В.Ю., Фамин И.В., Чесникова А.И., Шапошник И.И., Шостак Н.А. Миокардиты у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2021; 26 (11): 136–82. DOI: 10.15829/1560-4071-2021-4790.
  2. [Arutjunov G.P., Paleev F.N., Moiseeva O.M., Dragunov D.O., Sokolova A.V., Arutjunov A.G., Zhirov I.V., Blagova O.V., Privalova E.V., Gabrusenko S.A., Garganeeva A.A., Gendlin G.E., Giljarevskij S.R., Dupljakov D.V., Zajrat’janc O.V., Karateev D.E., Koziolova N.A., Kosmacheva E.D., Kochetov A.G., Lopatin Ju.M., Melehov A.V., Mitrofanova L.B., Narusov O.Ju., Nasonova S.N., Nedostup A.V., Nikulina S.Ju., Orlova Ja.A., Poteshkina N.G., Rebrov A.P., Saidova M.A., Sedov V.P., Sinicyn V.E., Sitnikova M.Ju., Skvorcov A.A., Skibickij V.V., Stukalova O.V., Tarlovskaja E.I., Tereshhenko S.N., Usov V.Ju., Famin I.V., Chesnikova A.I., Shaposhnik I.I., Shostak N.A.. 2020 Clinical practice guidelines for Myocarditis in adults. Russian Journal of Cardiology. 2021; 26 (11): 136–82 (in Russian)]
  3. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 386 (9995): 743–800. DOI: 10.1016/S0140-6736(15)60692-4
  4. Kyto V., Sipila J., Rautava P. Gender differences in myocarditis: a nationwide study in Finland. European Heart J. 2013; 34 (1): 644–5. DOI: 10.1093/eurheartj/eht309.3505
  5. Caforio A.L.P., Pankuweit S., Arbustini E., Basso C., Gimeno-Blanes J., Felix S.B., Fu M., Heliö T., Heymans S., Jahns R., Klingel K., Linhart A., Maisch B., McKenna W., Mogensen J., Pinto Y.M., Ristic A., Schultheiss H.-P., Seggewiss H., Tavazzi L., Thiene G., Yilmaz A., Charron P., Elliott P.M. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart J. 2013; 34 (33): 2636–48. DOI: 10.1093/eurheartj/eht210
  6. Caforio A.L.P. Myocarditis. Pathogenesis, Diagnosis and Treatment. Springer Nature Switzerland AG. 2020; 353.
  7. Elamm C., Fairweather D.L., Cooper L.T. Pathogenesis and diagnosis of myocarditis. Heart. 2012; 98: 835–40. DOI: 10.1136/heartjnl-2012-301686
  8. Благова О.В., Осипова Ю.В., Недоступ А.В., Коган Е.А., Сулимов В.А. Клинические, лабораторные и инструментальные критерии миокардита, установленные в сопоставлении с биопсийным исследованием миокарда (алгоритм неинвазивной диагностики). Терапевтический архив. 2017; 89 (9): 30–41. DOI: 10.17116/terarkh201789930-40
  9. [Blagova O.V., Osipova Ju.V., Nedostup A.V., Kogan E.A., Sulimov V.A. Сlinical, laboratory and instrumental criteria of myocarditis established in comparison with myocardial biopsy examination (noninvasive diagnostic algorithm). Terapevticheskii Arkhiv. 2017; 89 (9): 30–41 (in Russian)]
  10. Thomas Aretz H. Myocarditis: The Dallas criteria. Human Pathology. 1987; 18 (6): 619–24. DOI: 10.1016/S0046-8177(87)80363-5.
  11. Suresh A., Martens P., Tang W.H.W. Biomarkers for Myocarditis and Inflammatory Cardiomyopathy. Curr. Heart Fail. Rep. 2022; 19 (5): 346–55. DOI:10.1007/s11897-022-00569-8.
  12. Arenz C. miRNA Maturation. Methods and protocols. Methods in Molecular Biology 1095. 2014. ISBN 9781627037020.
  13. Wang J., Han B. Dysregulated CD4+ T Cells and microRNAs in Myocarditis. Front. Immunol. 2020; 11: 1–15. DOI:10.3389/fimmu.2020.00539.
  14. Calderon-Dominguez M., Belmonte T., Quezada-Feijoo M., Ramos-Sánchez M., Fernández-Armenta J., Pérez-Navarro A., Cesar S., Peña-Peña L., Vea À., Llorente-Cortés V., Mangas A., De Gonzalo-Calvo D., Toro R. Emerging role of microRNAs in dilated cardiomyopathy: evidence regarding etiology. Transl. Res. 2020; 215: 86–101. DOI:10.1016/j.trsl.2019.08.007.
  15. Marketou M., Kontaraki J., Fragiadakis K., Konstantinou J., Maragkoudakis S., Lempidakis D., Plevritaki A., Plataki M., Papadopoulos D., Vougia D., Fragiadakis K., Kassotakis S., Theodosaki O., Vardas P., Parthenakis F. MicroRNA-208b gene expression levels as a biomarkers of left ventricular dysfunction in patients with acute myocarditis. Eur. Heart J. 2019; 40: 2056. DOI: 10.1093/eurheartj/ehz746.0505.
  16. Liu Y.L., Wu W.F., Xue Y., Gao M., Yan Y., Kong Q., Pang Y., Yang F. MicroRNA-21 and -146b are involved in the pathogenesis of murine viral myocarditis by regulating TH-17 differentiation. Arch. Virol. 2013; 158 (9): 1953–63. DOI:10.1007/s00705-013-1695-6.
  17. Li M., Chen X., Chen L., Chen K., Zhou J., Song J. MiR-1-3p that correlates with left ventricular function of HCM can serve as a potential target and differentiate HCM from DCM. J. Transl. Med. 2018; 16 (1): 1–10. DOI: 10.1186/s12967-018-1534-3.
  18. Xue Y.M., Chen M.G., Chen D.W., Wu W.F., Liu Y.L., Lin F.H. The effect of microRNA-21 on myocardial fibrosis in mice with chronic viral myocarditis. Zhonghua Xin Xue Guan Bing Za Zhi. 2018; 46 (6): 450–7. DOI:10.3760/cma.j.issn.0253-3758.2018.06.008.
  19. Zhang X., Gao X., Hu J., Xie Y., Zuo Y., Xu H., Zhu S. ADAR1p150 forms a complex with dicer to promote miRNA-222 activity and regulate PTEN expression in CVB3-induced viral myocarditis. Int. J. Mol. Sci. 2019; 20 (2): 1–16. DOI:10.3390/ijms20020407.
  20. Corsten M.F., Papageorgiou A., Verhesen W., Carai P., Lindow M., Obad S., Summer G., Coort S.L.M., Hazebroek M., Van Leeuwen R., Gijbels M.J.J., Wijnands E., Biessen E.A.L., De Winther M.P.J., Stassen F.R.M., Carmeliet P., Kauppinen S., Schroen B., Heymans S. MicroRNA profiling identifies microRNA-155 as an adverse mediator of cardiac injury and dysfunction during acute viral myocarditis. Circ. Res. 2012; 111 (4): 415–25. DOI:10.1161/CIRCRESAHA.112.267443.
  21. Zhou Y., Song Y., Shaikh Z., Li H., Zhang H., Caudle Y., Zheng S., Yan H., Hu D., Stuart C., Yin D.. MicroRNA-155 attenuates late sepsis-induced cardiac dysfunction through JNK and β-arrestin 2. Oncotarget. 2017; 8 (29): 47317–29.
  22. Mahdavi F.S., Mardi S., Mohammadi S., Ansari S., Yaslianifard S., Fallah P., Mozhgani S. MicroRNA-146: Biomarker and Mediator of Cardiovascular Disease. Dis. Markers. 2022; 2022: 1–13. DOI: 10.1155/2022/7767598.
  23. Corsten M.F., Dennert R., Jochems S., Kuznetsova T., Devaux Y., Hofstra L., Wagner D.R., Staessen J.A., Heymans S., Schroen B.. Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. Circ. Cardiovasc. Genet. 2010; 3 (6): 499–506. DOI: 10.1161/CIRCGENETICS.110.957415
  24. Lewandowski P., Goławski M., Baron M., Reichman-Warmusz E., Wojnicz R. A systematic review of miRNA and cfDNA as potential biomarkers for liquid biopsy in myocarditis and inflammatory dilated cardiomyopathy. Biomolecules. 2022; 12 (10): 1476. DOI: 10.3390/biom12101476
  25. Zhang Y., Li X., Wang D., Jiang X., Zhang M. Lv K. Serum exosome microRNA panel as a noninvasive biomarker for molecular diagnosis of fulminant myocarditis. Mol. Ther. Methods Clin. Dev. 2021; 20: 142–51. DOI: 10.1016/j.omtm.2020.11.006.
  26. Yu M., Liang W., Xie Y., Long Q., Cheng X., Liao Y.H., Yuan J. Circulating miR-185 might be a novel biomarker for clinical outcome in patients with dilated cardiomyopathy. Sci. Rep. 2016; 6: 1–10. DOI: 10.1038/srep33580.